close
Add to watchlist
Celsion Corp (CLSN)
Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. Its lead product includes ThermoDox, an oncology drug, which is a heat activated liposomal encapsulation of doxorubicin is in Phase III clinical trials for primary liver cancer and Phase II study for recurrent chest wall breast cancer. The company has a licensing agreement with Yakult Honsha to commercialize and market ThermoDox for the Japanese market; and a licensing agreement with Duke University to patent Duke's thermo-liposome technology in the United States, and to future patents received by Duke in Canada, Europe, Japan, and Australia. It has a joint research agreement with Royal Phillips Electronics to evaluate the combination of Phillips' high intensity focused ultrasound with Celsion's heat activated liposomal technology to develop new cancer drugs. Celsion Corporation was founded in 1982 and is based in Columbia, Maryland.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 1.70 |
| Volume | 497421 |
| Volume Avg | 494616 |
| 52 Week High | 4.37 |
| 52 Week Low | 1.64 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -1.33 |
| EPS change Q/Q | -10.53% |
| EPS change Q/Q Yr ago | -121.05% |
| EPS change Q/Q next Q est | -82.61% |
| EPS change Y/Y | -3.95% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.23 |
| EPS next Y est | -0.89 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |